Who is sponsoring NCT05487976?

NCT05487976 is sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd..

What drugs are being tested in NCT05487976?

Interventions in NCT05487976: Recombinant human activated coagulation factor VII for injection.

What condition does NCT05487976 study?

NCT05487976 studies Hemophilia A, Hemophilia B.

Is NCT05487976 still recruiting?

NCT05487976 is currently status unknown. Last updated 2 August 2022.

Last reviewed 2022-08-02 · How we verify

NCT05487976

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase III Clinical Study of the Efficacy and Safety of Recombinant Human Activated Coagulation Factor VII for Injection in Patients With Hemophilia With Inhibitors

Status unknown Phase 3 Last updated 2 August 2022

What this trial tests

Phase 3 trial testing Recombinant human activated coagulation factor VII for injection in Hemophilia A in 50 participants. Status unknown.

Timeline

28 April 2022

Primary endpoint
1 April 2023

1 April 2023

Quick facts

Lead sponsor	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	50
Start date	28 April 2022
Primary completion	1 April 2023
Estimated completion	1 April 2023
Sites	9 locations across China

Drugs / interventions tested

Recombinant human activated coagulation factor VII for injection — full drug profile →

Conditions studied

Hemophilia A — all drugs for Hemophilia A →
Hemophilia B — all drugs for Hemophilia B →

Sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — full company profile →

Who can join

Adults 18 to 65, any sex, with Hemophilia A or Hemophilia B. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Number of bleeding Effective rate of hemostasis
Time frame: Each new blood event was assessed within 12 hours of initial treatment
Hemostasis is effective after the bleeding event if the bleeding event has not received other treatment within 12 hours since the first treatment and achieved moderate or above remission (based on the four-point scoring standard)
Activity recovery of first dose
Time frame: Within 1 hour of completion of infusion
The peak coagulation factor VII activity measured within 1 hour after the end of the infusion was subtracted from the baseline coagulation factor VII activity and expressed as \[IU/ml\]/\[IU/kg\].

Sponsor's own description

Human coagulation factor VII is a vitamin K-dependent serine endogenous protease, and its activated form plays an important role in the coagulation process. Recombinant human activated coagulation factor VII is an activated state coagulation factor VII obtained by recombinant means.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Hemostats in the clinic.
Joshi M, Zhao Z, Mitragotri S. · · 2024 · cited 4× · PMID 39545083 · DOI 10.1002/btm2.10673

Verify or expand the search:

Other recruiting trials for Hemophilia A

Currently open trials in the same condition.

NCT07416526 — A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A · Phase 3 · recruiting
NCT07416604 — A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A · Phase 3 · recruiting
NCT07523399 — Joint Health, Balance and Quality of Life in Adults With Hemophilia A · recruiting
NCT06833983 — To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A · Phase 3 · recruiting
NCT06579144 — Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A · Phase 1 · recruiting

Other Chia Tai Tianqing Pharmaceutical Group Co., Ltd. trials

Trials by the same sponsor.

NCT06990776 — A Clinical Trial to Evaluate the Efficacy and Safety of TQA3605 Tablets in Treatment-naive Chronic HBV-infected Subjects · Phase 2 · withdrawn
NCT06851442 — Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced o · Phase 1, PHASE2 · terminated
NCT06711991 — A Clinical Trial of TQC3927 Powder for Inhalation in Chronic Obstructive Pulmonary Disease · Phase 1 · completed
NCT06672276 — To Evaluate the Pharmacokinetics and Safety of TQD3606 for Injection in Subjects With Renal Insufficiency · Phase 1 · completed
NCT06644417 — Clinical Study of TQA3605 Tablets Combined With Nucleoside (Acid) Analogs (NAs) Drugs Compared With NAs Drugs in the Tre · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05487976 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Last refreshed: 2 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05487976.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing